AtriCure Stockholders Approve Stock Incentive Plan Amendment

The latest update is out from Atricure ( (ATRC) ).

At the 2025 Annual Meeting of Stockholders held on May 19, AtriCure’s stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the shares available for issuance from 2,800,000 to 4,500,000. This amendment aims to attract and retain key personnel by allowing directors, officers, and employees to acquire equity interests, aligning their interests with those of the stockholders. Additionally, the meeting saw the election of nine directors, the ratification of Deloitte & Touche LLP as the accounting firm, and advisory votes on executive compensation and its frequency, with the decision to hold annual advisory votes on executive compensation.

The most recent analyst rating on (ATRC) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Atricure stock, see the ATRC Stock Forecast page.

Spark’s Take on ATRC Stock

According to Spark, TipRanks’ AI Analyst, ATRC is a Neutral.

AtriCure’s overall score reflects strong revenue growth and operational efficiency, countered by ongoing profitability challenges and a mixed technical outlook. The earnings call suggests positive momentum with product successes, but areas such as minimally invasive ablation sales and rising expenses present risks. The valuation is not attractive due to negative earnings, despite a stable balance sheet.

To see Spark’s full report on ATRC stock, click here.

More about Atricure

AtriCure, Inc. operates in the medical device industry, focusing on developing and selling innovative surgical treatments for atrial fibrillation and related conditions. The company provides a range of products and services aimed at improving patient outcomes and enhancing surgical procedures.

Average Trading Volume: 637,145

Technical Sentiment Signal: Sell

Current Market Cap: $1.6B

For a thorough assessment of ATRC stock, go to TipRanks’ Stock Analysis page.